N@N

Diamyd Medical Publishes the Annual Report for 2009/2010

_{//science-technology.news-articles.net/content/2 .. l-publishes-the-annual-report-for-2009-2010.html}
^{Published in Science and Technology on Thursday, November 25th 2010 at 1:00 GMT by Market Wire}  

STOCKHOLM--([ BUSINESS WIRE ])--Regulatory News:

Diamyd Medical's (STO:DIAMB)(Pink Sheets:DMYDY) Annual Report for 2009/2010 is from today available in Swedish on the company website, [ www.diamyd.com ].

The printed version of the Annual Report can be ordered from Diamyd Medical by mail: Diamyd Medical, Karlavgen 108, SE-115 26 Stockholm, or by e-mail to [ investor.relations@diamyd.com ].

Diamyd Medical's Annual General Meeting takes place on Thursday December 9, 2010 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm.

The English translation of the Annual Report will be available in approximately two weeks.

About Diamyd Medical Diamyd Medical is a Swedish pharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and pain. The Diabetes business area consists of the antigen-based candidate drug Diamyd® for the treatment and prevention of autoimmune diabetes. Phase III studies of Diamyd® are currently in progress in Europe and the US. In 2010 the Company signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., for the development and commercialization of Diamyd®. The Pain business area consists of development projects that use the Company's proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat chronic pain. A Phase I study of the candidate drug NP2 Enkephalin for cancer pain is ongoing, and the Company plans to initiate a Phase II study.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: [ www.diamyd.com ].

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.

Diamyd Medical AB (publ.) Karlavgen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68 E-mail: [ info@diamyd.com ]. VAT no: SE556530-142001.

This information was brought to you by Cision [ http://www.cisionwire.com ]